Bupropion Significantly Affects MDMA Metabolism and Effects
Bupropion directly interacts with MDMA by increasing MDMA plasma concentrations, prolonging its subjective effects, and reducing its cardiovascular stimulation—making this a clinically significant drug interaction that should be avoided or approached with extreme caution. 1
Mechanism of Interaction
Bupropion inhibits both the dopamine and norepinephrine transporters (DAT and NET), which are the same transporters through which MDMA releases dopamine and norepinephrine 1. This creates a bidirectional pharmacokinetic interaction:
- Bupropion increases MDMA levels: When combined, bupropion elevates plasma MDMA concentrations and extends the duration of MDMA's subjective mood effects 1
- MDMA increases bupropion levels: Conversely, MDMA also raises plasma bupropion concentrations, creating a potentially dangerous escalation of both drugs 1
Clinical Implications
The interaction produces paradoxical effects:
- Enhanced mood effects: The subjective psychotropic effects of MDMA are prolonged and intensified 1
- Reduced cardiac stimulation: Bupropion blunts MDMA-induced elevations in plasma norepinephrine and heart rate response 1
- Risk of toxicity: Higher concentrations of both drugs increase the risk of adverse effects, including seizures (bupropion lowers seizure threshold 2) and serotonin syndrome
Bupropion's CYP2D6 Inhibition
Bupropion is a moderate inhibitor of CYP2D6 3, 4, 5. While MDMA metabolism involves multiple pathways including CYP2D6-mediated O-demethylenation 6, the primary interaction mechanism appears to be transporter-mediated rather than purely metabolic 1. However, the CYP2D6 inhibition adds another layer of interaction potential, as it can affect the metabolism of numerous other drugs 3.
Trazodone and MDMA
No direct evidence exists regarding trazodone-MDMA interactions in the provided literature. However, critical safety concerns exist:
Serotonin Syndrome Risk
Both trazodone and MDMA have serotonergic activity:
- MDMA is a potent serotonin releaser and reuptake inhibitor 6
- Trazodone has serotonergic properties and is listed among medications that increase serotonin syndrome risk when combined with other serotonergic agents 7, 8
- The combination creates high risk for serotonin syndrome, characterized by neuromuscular excitation, autonomic dysfunction, and potentially fatal hyperthermia 7, 8, 6
Sedation and CNS Depression
Trazodone causes significant somnolence 9 and when combined with MDMA's stimulant effects followed by its depressant phase, unpredictable CNS effects may occur.
Clinical Recommendations
For patients on bupropion: MDMA use should be strongly discouraged due to:
- Elevated plasma concentrations of both drugs 1
- Prolonged drug effects 1
- Increased seizure risk (bupropion reduces seizure threshold 2, 3)
- Unpredictable cardiovascular effects 1
For patients on trazodone: MDMA use carries severe risk of serotonin syndrome, which can be fatal 7, 8. The combination should be absolutely avoided.
Common Pitfalls
- Assuming reduced heart rate response means the interaction is "safer"—the elevated drug concentrations still pose significant toxicity risk 1
- Underestimating serotonin syndrome risk with any serotonergic combination 7, 8
- Not recognizing that bupropion's CYP2D6 inhibition persists for at least 7 days after discontinuation 3